Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi ...
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the l ...
NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...
CS014 is a novel, orally administered HDAC inhibitor with potential to address underlying disease mechanisms in severe cardiopulmonary diseases. With a completed Phase I study and a broadened ...
In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.
A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...
The blueprint was developed through working groups and workshops hosted by the UK Textiles Pact during 2025, building on a cross-industry position statement released in summer 2025 by WRAP, the ...
Researchers at the Institute for Molecular Science (NINS, Japan) and SOKENDAI have demonstrated a more than 2000% voltage-induced enhancement of near-field nonlinear optical responses. To achieve this ...
A wide of array of advanced controllers arrived in 2025, marked by high integration and enhanced intelligence in solutions ...
Disrupting left superior frontal sulcus selectively impaired perceptual but not value-based decisions, revealing segregated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results